Comparative Pharmacology
Head-to-head clinical analysis: AUREOMYCIN versus OXY KESSO TETRA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AUREOMYCIN versus OXY KESSO TETRA.
AUREOMYCIN vs OXY-KESSO-TETRA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to the 30S ribosomal subunit, inhibiting protein synthesis by blocking aminoacyl-tRNA binding.
Oxycodone is a full opioid agonist with relative selectivity for the mu-opioid receptor, though it can interact with other opioid receptors at higher doses. The principal therapeutic action of oxycodone is analgesia. Like all full opioid agonists, there is no ceiling effect for analgesia with oxycodone. Oxycodone is combined with aspirin (OXY-KESSO-TETRA) for analgesic synergy.
250-500 mg orally every 6 hours; or 10-20 mg/kg/day intravenously divided every 12 hours
200 mg orally every 8 hours for 10 days.
None Documented
None Documented
Terminal elimination half-life: 8–12 hours (prolonged in renal impairment; may extend to 20–30 hours in anuria)
Terminal elimination half-life approximately 8-12 hours in adults with normal renal function; prolonged to 20-40 hours in moderate to severe renal impairment (CrCl <30 mL/min), necessitating dose adjustment.
Renal (70% unchanged), biliary/fecal (30% as metabolites and unchanged drug)
Primarily renal (60-70% as unchanged drug) via glomerular filtration and tubular secretion; approximately 20-30% is metabolized hepatically with metabolites excreted renally; less than 5% eliminated via bile/feces.
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic